| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CONMED Corporation$43.51
+0.83 (+1.94%)
D 34Pipeline Score MedTech · Commercial
Market Cap
1.12 B
EPS
1.78
P/E Ratio
21 $
Value Trade
24.18 M
SEC Financials
Q4 2025Dilution Risk
Revenue
373.20 M
R&D Expenses
14.90 M
Operating CF
42.67 M
Total Assets
2.33 B
Total Liabilities
1.29 B
Equity
1.03 B
D/E Ratio
12,345
2.76 %
Week
-4.15 %
1 Month
-16.56 %
3 Month
-9.66 %
6 Month
-73.34 %
5 Year
10,876.54 %
All Time
Cash Data
Cash Position
40.82 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Feb 17, 2026
Overview
Volume
437.72 K
52 Week Range
33.21 - 60.35
% held by Insiders
0.44 %
% held by Institutions
113.68 %
Enterprise Value
1.95 B
Total Shares
30.11 M
Short %
7.77 %
Float Shares
29.99 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CONMED Corporation
1Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D34
Pipeline Score $0M
Pipeline ValueValuation Signal
2
Drugs Scored—
rNPV / MCap Top 48%
Micro Cap (rank 476 of 913)
Percentile RankCONMED Corporation faces pipeline headwinds (34/100), with 2 assets in development.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CNMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CNMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CNMDCONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
CONMED Corporation has announced an expanded indication for its AirSeal Robotic Solution, which is now approved for use with Intuitive's 8 mm hex cannulas as part of the da Vinci 5 platform. This addition complements the existing indication for round cannulas, enhancing the product's compatibility with various da Vinci robotic systems. The expansion aims to improve surgical efficiency and patient outcomes.
Read more →CNMDCONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
CONMED Corporation will participate in the Society of Robotic Surgery Annual Meeting scheduled for July 23-26, 2026, in Fort Lauderdale, FL. Professor Nikhil Vasdev will present findings from a randomized controlled trial focusing on intraoperative and post-operative pain levels. This participation underscores CONMED's dedication to advancing robotic surgery techniques.
Read more →CNMDCONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
CONMED Corporation is scheduled to report its financial results for the second quarter of 2026 on July 29, 2026. This announcement is part of the company's regular financial reporting cycle. Further details regarding the performance metrics will be disclosed at that time.
Read more →CNMDCONMED Corporation Appoints John E. Gallagher as Chief Financial Officer
CONMED Corporation has announced the appointment of John E. Gallagher as its new Chief Financial Officer. This decision is part of the company's strategy to enhance its financial leadership. Gallagher brings extensive experience in finance and management to the role, which is expected to benefit the organization moving forward.
Read more →CNMD▼ -7.1%on this newsshared move
: CONMED Corporation Dalton Henry Investor Relations Analyst IR@conmed.com CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer Largo, Fla.
CONMED Corporation has appointed John E. Gallagher as its new Chief Financial Officer, effective July 15, 2026, succeeding Todd Garner, who will remain in an advisory role. Gallagher brings nearly 30 years of financial experience in the healthcare sector, having held leadership positions in various public companies. His background includes significant roles at Certara, Cue Health, and Becton, Dickinson & Co., indicating a wealth of expertise in managing corporate finance and global finance organizations. Both Gallagher and CONMED's CEO expressed optimism about his contributions to the company's strategic priorities and value creation for shareholders.
Read more →CNMDCONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
CONMED Corporation has appointed Celine Martin and Jeff Mirviss to its Board of Directors. This strategic move aims to enhance the company's leadership team. The appointments reflect CONMED's commitment to strengthening its governance and oversight capabilities.
Read more →CNMDCONMED Corporation Announces First Quarter 2026 Financial Results
CONMED Corporation reported its first quarter 2026 financial results, showing a slight decline in sales of 1.3% year-over-year, primarily due to the exit of certain GI products. However, the company experienced growth in international revenue and improved adjusted earnings per share. Management has raised its full-year revenue growth outlook, reflecting confidence in its higher-margin areas.
Read more →CNMDCONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
CONMED Corporation has scheduled the announcement of its financial results for the first quarter of 2026 on April 29, 2026. This announcement is part of the company's regular financial reporting process. Further details regarding the financial performance will be provided at that time.
Read more →CNMDJ.P. Morgan 44 th Annual Healthcare Conference Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer January 12 th , 2026 Forward - Looking Information Thi
At the J.P. Morgan 44th Annual Healthcare Conference, CONMED's management discussed forward-looking statements regarding the company's financial outlook and product innovations. They presented insights into expected revenue growth across various sectors, particularly in sports medicine and general surgery. The emphasis was placed on the growth potential of AirSeal technology and BioBrace implants, which are gaining traction due to legislative support and clinical validation. However, risks associated with forward-looking indicators were acknowledged, including uncertainties in projections related to financial performance.
Read more →CNMD▼ -9.4%on this news
: CONMED Corporation Todd W. Garner Chief Financial Officer ToddGarner@conmed.com CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines Concludes Distribution Agreement with
CONMED Corporation announced a strategic exit from its gastroenterology product lines, effective January 1, 2026. This decision aims to optimize their portfolio and focus on core areas such as minimally invasive surgery and orthopedic soft tissue repair. The company concluded its distribution agreement with Gore for the VIABIL stent earlier than planned. Despite this transition, CONMED has reaffirmed its revenue and EPS guidance for 2025, indicating confidence in its core business growth.
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer ToddGarner@conmed.com CONMED Corporation Adds Kim Kelderman to its Board of Directors Largo, Fla.
CONMED Corporation has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman brings a wealth of experience from roles at Bio-Techne and Thermo Fisher Scientific, where he led various significant business segments. The leadership at CONMED is optimistic about the value his insights and track record in life sciences will bring as they focus on delivering stakeholder value and achieving their long-term vision.
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer ToddGarner@conmed.com Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Office
Martha Aronson will step down from the CONMED Corporation Board of Directors to become the President and CEO of Merit Medical Systems, Inc. Her resignation is effective July 7, 2025, following her significant contributions since joining the board in February 2016. During her tenure, Aronson has focused on improving strategic growth and governance excellence, playing a key role in guiding the company. The President and CEO of CONMED expressed gratitude for her service and wished her success in her new position.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2025 Financial Results Largo, Florida
CONMED Corporation has announced its financial results for the first quarter of 2025, highlighting a positive start to the year. The company expects its full-year reported revenue to be between $1.350 billion and $1.378 billion, an increase from previous guidance. Additionally, the adjusted diluted net earnings per share for 2025 are projected to rise, suggesting strong operational performance. However, potential tariff implications could negatively impact earnings later in the year.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Adds Mark Kaye to its Board of Directors Largo, Fla.
CONMED Corporation has announced the appointment of Mark Kaye to its Board of Directors, effective February 24th, 2025. Kaye brings significant expertise in finance, accounting, risk management, and corporate governance, which the board believes will enhance the company’s strategic direction. With a background as CFO at Elevance Health and Moody’s Corporation, Kaye is expected to contribute valuable insights that will benefit CONMED's growth opportunities.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results Largo, Fla.
CONMED Corporation reported its financial results for the fourth quarter and full year ended December 31, 2024, showing solid growth in sales and earnings. The company highlighted improved profitability in the fourth quarter despite challenges with supply chain issues. For 2025, CONMED estimates revenue between $1.344 billion and $1.372 billion, indicating a modest growth outlook. However, the business anticipates currency headwinds and potential impacts from recent tariffs. Management remains focused on enhancing operations to strengthen the foundation for future growth.
Read more →CNMDJ.P. Morgan 43rd Annual Healthcare Conference Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, whic
During the J.P. Morgan 43rd Annual Healthcare Conference, CONMED presented forward-looking information that may involve various risks and uncertainties impacting its performance. The company's objectives include long-term growth and enhancing shareholder value through strategic initiatives. CONMED highlighted its focus on evolving its product offerings and expanding market share in attractive segments such as orthopedics and general surgery. While management expressed optimism about future growth, they also indicated the challenges posed by different market conditions and competition.
Read more →CNMDCONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2024 Financial Results Largo, Florida
CONMED Corporation announced its third quarter financial results for 2024, indicating a revenue forecast of $1.300 billion to $1.305 billion. The company reported net income of $48.984 million for the quarter, significantly up from the previous year's $15.837 million. While the overall performance was in line with expectations, the full-year revenue guidance was lowered compared to prior projections. The company also highlighted operational challenges due to disruption from hurricanes affecting their Southeast locations.
Read more →CNMDCONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Preliminary Third Quarter Financial Information
CONMED Corporation has announced its preliminary financial information for the third quarter of 2024, expecting revenues of $315 million to $318 million. The company also anticipates that its adjusted diluted net earnings per share will grow beyond the previously provided guidance of 9% to 11%. Full financial results will be reported on October 30, 2024, and a conference call will be held to discuss these results. This preliminary information is subject to change as the financial closing procedures for the quarter have not yet been completed.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2024 Financial Results Largo, Florida
CONMED Corporation reported its financial results for the second quarter of 2024, highlighting a net sales increase to $332.1 million, up 4.5% year-over-year. Despite this growth, the company's full-year revenue guidance has been lowered due to ongoing supply chain challenges and the impact of foreign currency. Adjusted earnings per share expectations have also been revised downward. The management remains focused on addressing these challenges and driving long-term growth.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2024 Financial Results Largo, Florida
CONMED Corporation (NYSE: CNMD) announced its financial results for the first quarter of 2024, showcasing significant growth in both revenue and net income compared to the previous year. The company reported net sales of $312.3 million, marking a 5.7% increase year-over-year, along with a notable improvement in gross profit margins. However, CONMED anticipates challenges from approximately $10 million in foreign currency exchange rate impacts, leading to a slight downward adjustment in its full-year revenue and earnings guidance. The management remains optimistic about the diverse product portfolio's potential to drive further growth.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results Largo, Florida
CONMED Corporation (NYSE: CNMD) announced its financial results for the fourth quarter and full-year 2023, reporting record revenues. The company achieved a substantial growth in net sales, with expectations for continued revenue increases in 2024. Additionally, adjusted diluted net earnings per share are projected to see a significant rise of approximately 25% year-over-year. This positive performance highlights the effectiveness of CONMED's global strategy and product offerings in the medical sector.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2023 Financial Results Largo, Florida
CONMED Corporation announced its financial results for the third quarter of 2023, highlighting significant revenue and earnings growth. The company has increased its full-year revenue guidance to between $1.240 billion and $1.260 billion, reflecting a robust performance across its business units. Adjusted diluted net earnings per share expectations have also risen, now projected between $3.45 and $3.55. The results indicate a strong market position and positive outlook for the remainder of the year.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2023 Financial Results Largo, Florida
CONMED Corporation announced its financial results for the second quarter of 2023, highlighting strong performance in both Orthopedics and General Surgery. The company reported net sales of $317.7 million, a 14.6% increase from the previous year. Additionally, CONMED raised its full-year revenue guidance to between $1.230 billion and $1.260 billion, reflecting increased optimism in its growth outlook. Adjusted diluted earnings per share for the year is now expected to range from $3.40 to $3.55. The management expressed confidence in their ability to innovate and sustain growth.
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2023 Financial Results Largo, Florida
CONMED Corporation has announced its financial results for the first quarter of 2023, showing a revenue increase of 21.9% year-over-year, bringing total net sales to $295.5 million. The company raised its revenue guidance for the full year to between $1.205 billion and $1.250 billion, reflecting a positive outlook. However, net income saw a significant decrease compared to the previous year, and foreign exchange fluctuations are expected to create challenges. The management expressed confidence in their strategy and commitment to enhancing customer service.
Read more →CNMD▲ +8%on this news
: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2022 Financial Results Largo, Florida
CONMED Corporation (NYSE: CNMD) announced its financial results for the fourth quarter and full year 2022, revealing significant disruptions due to a new warehouse management system. Despite successful acquisitions and a commitment to product innovation, the company faced a net loss and declining sales across several segments. Management indicates a focus on increasing efficiency and capacity, with expectations of positive revenue growth in 2023, despite projected foreign exchange challenges.
Read more →CNMDCONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Withdraws 2022 Financial Outlook due to Temporary Impact from Software Implementation;
CONMED Corporation Withdraws 2022 Financial Outlook due to Temporary Impact from Software Implementation; Provides 2023 Financial Outlook LARGO, Fla. November 15, 2022 CONMED Corporation (NYSE: CNMD) today announced that due to a temporary disruption resulting from the impleme
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2022 Financial Results Largo, Florida
CONTACT : CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2022 Financial Results Largo, Florida, October 26, 2022 - CONMED Corporation (NYSE: CNMD) today announced financial results
Read more →CNMDCONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Completes Acquisition of Biorez, Inc. Largo, Florida
NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Completes Acquisition of Biorez, Inc. Largo, Florida, August 9, 2022 CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announce
Read more →CNMDCONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Announces Definitive Agreement to Acquire Biorez, Inc. Through this acquisition, CONMED acquires next generati
NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Announces Definitive Agreement to Acquire Biorez, Inc. Largo, Florida, August 1, 2022 CONMED Corporation (NYSE: CNMD) today announced a definitive agreement
Read more →CNMDCONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2022 Financial Results Largo, Florida
CONMED Corporation Announces Second Quarter 2022 Financial Results Largo, Florida, July 27, 2022 CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended Second Quarter 2022 Highlights I m proud that our team drove strong revenue growth in
Read more →CNMD▼ -6.1%on this news
CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Completes Acquisition of In2Bones Global, Inc. Largo, Florida
NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Completes Acquisition of In2Bones Global, Inc. June 13, 2022 CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced a
Read more →CNMDCONFIDENTIAL NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-241-2975 ToddGarner@conmed.com CONMED Corporation Announces Pricing of Upsized $700 Million Offering of Convertible Senior Not
NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-241-2975 ToddGarner@conmed.com CONMED Corporation Announces Pricing of Upsized $700 Million Offering of Convertible Senior Notes Largo, Florida, June 1, 2022 CONMED Corporation (NYSE: CNMD) tod
Read more →CNMDCONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Private Offering of $600 Million of Convertible Senior Notes Largo, Florida
NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Private Offering of $600 Million of Convertible Senior Notes Largo, Florida, May 31, 2022 CONMED Corporation (NYSE: CNMD) t
Read more →CNMDCONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2022 Financial Results Largo, Florida
Chief Financial Officer ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2022 Financial Results Largo, Florida, May 4, 2022 CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended First Quarter 2022 Highlights I am please
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2021 Financial Results Largo, Florida
NEWS RELEASE CONTACT : CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2021 Financial Results Largo, Florida, January 26, 2022 - CONMED Corporation (NYSE: CNMD) today
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter Financial Results Largo, Florida
NEWS RELEASE CONTACT : CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter Financial Results Largo, Florida, October 27, 2021 - CONMED Corporation (NYSE: CNMD) today announced financial
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter Financial Results Largo, Florida
NEWS RELEASE CONTACT : CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter Financial Results Largo, Florida, July 28, 2021 - CONMED Corporation (NYSE: CNMD) today announced financial r
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter Financial Results Largo, Florida
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter Financial Results Largo, Florida, April 28, 2021 --- CONMED Corporation (NYSE: CNMD) today announced financial re
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2020 Financial Results Largo, Florida
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2020 Financial Results Largo, Florida, January 27, 2021 --- CONMED Corporation (NYSE: CNMD) today
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2020 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2020 Financial Results Utica, New York, October 28, 2020 --- CONMED Corporation (NYSE: CNMD) today announced fina
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2020 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2020 Financial Results Utica, New York, July 29, 2020 --- CONMED Corporation (NYSE: CNMD) today announced financ
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2020 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2020 Financial Results Utica, New York, April 29, 2020 --- CONMED Corporation (NYSE: CNMD) today announced financ
Read more →CNMDCONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Amendment to its Existing Credit Agreement Utica, New York
NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Amendment to its Existing Credit Agreement Utica, New York, April 20, 2020 CONMED Corporation (NYSE: CN
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Changes to Board Leadership Mark Tryniski to Stand for Reelection as Director
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Changes to Board Utica, New York, March 16, 2020 - CONMED Corporation (NYSE: CNMD) today announced that Mark E. Tryniski, Chair
Read more →CNMD: Conmed Corporation Todd W. Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2019 Financial Results Utica, New York
NEWS RELEASE CONTACT : Conmed Corporation Todd W. Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2019 Utica, New York, January 29, 2020 --- CONMED Corporation (Nasdaq: CNMD) today announced fi
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2019 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2019 Financial Results Utica, New York, October 30, 2019 --- CONMED Corporation (Nasdaq: CNMD) today announced fi
Read more →CNMD: CONMED Corporation Todd W. Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Adds LaVerne Council and Barbara Schwarzentraub to its Board of Directors Utica, New
NEWS RELEASE CONTACT : CONMED Corporation Todd W. Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Adds LaVerne Council and Barbara Schwarzentraub to its Utica, New York, September 23, 2019 - CONMED Corporation (NASDAQ: CNMD) a
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2019 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2019 Financial Results Utica, New York, July 31, 2019 --- CONMED Corporation (Nasdaq: CNMD) today announced fina
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com Dirk Kuyper to Step Down from CONMED Corporation Board of Directors Effective
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com Dirk Kuyper to Step Down from CONMED Corporation Effective August 1, 2019 Utica, New York, June 18, 2019 - CONMED Corporation (NASDAQ: CNMD) today announced
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2019 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2019 Financial Results Utica, New York, April 24, 2019 --- CONMED Corporation (Nasdaq: CNMD) today announced fina
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Completes Acquisition of Buffalo Filter LLC Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Completes Acquisition of Buffalo Filter LLC Utica, New York, February 11, 2019 CONMED Corporation (NASDAQ: CNMD) today announced that it has completed its
Read more →CNMDCONMED Corporation Announces Pricing of $300 Million Offering of Convertible Senior Notes Utica, New York
CONMED Corporation Announces Pricing of $300 Million Offering of Convertible Senior Notes York January 24, 2019 CONMED Corporation (NASDAQ: CNMD) today announced the pricing of $300 million aggregate principal amount of 2.625% convertible senior notes due 2024 in a private offe
Read more →CNMDCONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Private Offering of $275 Million of Convertible Senior Notes Utica, New York
NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Private Offering of $275 Million of Convertible Senior Notes Utica, New York, January 23, 2019 CONMED Corporation (NASDAQ:
Read more →CNMDCONMED Announces Definitive Agreement to Acquire Buffalo Filter LLC Transaction adds category leader in the surgical smoke evacuation market to its General Surgery portfolio CONMED to host conference call today at 4:30 p
CONMED Announces Definitive Agreement to Acquire Buffalo Filter LLC UTICA, N.Y. (BUSINESS WIRE) Dec. 13, 2018 CONMED Corporation (NASDAQ:CNMD) today announced a definitive agreement to acquire privately-held Buffalo Filter LLC (Buffalo Filter) for $365 million on a cash-free, d
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2018 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2018 Financial Results Utica, New York, November 1, 2018 --- CONMED Corporation (Nasdaq: CNMD) today announced fi
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2018 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Second Quarter 2018 Financial Results Utica, New York, August 1, 2018 --- CONMED Corporation (Nasdaq: CNMD) today announced fin
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2018 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2018 Financial Results Utica, New York, April 25, 2018 --- CONMED Corporation (Nasdaq: CNMD) today announced fina
Read more →CNMD: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2017 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2017 Financial Results Utica, New York, January 31, 2018 --- CONMED Corporation (Nasdaq: CNMD) t
Read more →CNMDCONMED Corporation Luke A. Pomilio Advisor to Chief Financial Officer 315-624-3202 CONMED Corporation Appoints Todd W. Garner as Executive Vice President and Chief Financial Officer Utica, New York
NEWS RELEASE CONTACT: CONMED Corporation Luke A. Pomilio Advisor to Chief Financial Officer 315-624-3202 CONMED Corporation Appoints Todd W. Garner as Executive Vice President and Chief Financial Officer Utica, New York, January 2, 2018 CONMED Corporation (NASDAQ: CNMD) tod
Read more →CNMDCONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Third Quarter 2017 Financial Results Utica, New York
NEWS RELEASE CONTACT: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Third Quarter 2017 Financial Results Utica, New York, November 2, 2017 CONMED Corporation (Nasdaq: CNMD) today announced financi
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2017 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2017 Financial Results Utica, New York, July 26, 2017 --- CONMED Corporation (Nasdaq: CNMD) today announced
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces First Quarter 2017 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces First Quarter 2017 Financial Results Utica, New York, April 26, 2017 --- CONMED Corporation (Nasdaq: CNMD) today announced
Read more →CNMDCONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 CONMED Corporation Announces Jury Verdict in Delaware Litigation Against SurgiQuest Utica, New York
CONMED Corporation Announces Jury Verdict in Delaware Litigation Against SurgiQuest Utica, New York, April 11, 2017 CONMED Corporation (NASDAQ: CNMD) today announced that a jury in the United State Federal District Court for the District of Delaware returned a verdict finding
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2016 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2016 Utica, New York, February 1, 2017 --- CONMED Corporation (Nasdaq: CNMD) today announce
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Third Quarter 2016 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Third Quarter 2016 Financial Utica, New York, October 27, 2016 --- CONMED Corporation (Nasdaq: CNMD) today announced financial r
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2016 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2016 Financial Results Utica, New York, July 27, 2016 --- CONMED Corporation (Nasdaq: CNMD) today announced
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces First Quarter 2016 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces First Quarter 2016 Financial Results Utica, New York, April 27, 2016 --- CONMED Corporation (Nasdaq: CNMD) today announced
Read more →CNMDCONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 CONMED Corporation Adds Health Care Executive Martha Goldberg Aronson to its Board of Directors Utica, New York
NEWS RELEASE CONTACT: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 CONMED Corporation Adds Health Care Executive Martha Goldberg Aronson to its Board of Directors Utica, New York, February 23, 2016 CONMED Corporation (NASDAQ: CNMD) today announced
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2015 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Fourth Quarter and Fiscal Year 2015 Financial Results Utica, New York, January 27, 2016 --- CONMED Corporation (Nasdaq: CN
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 CONMED Completes Acquisition of SurgiQuest, Inc. Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 CONMED Completes Acquisition of SurgiQuest, Inc. Utica, New York, January 4, 2016 CONMED Corporation (NASDAQ: CNMD) today announced that it has completed its p
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 CONMED Announces Definitive Agreement to Acquire SurgiQuest, Inc. Significantly bolsters CONMED s Advanced Surgical portfolio
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 CONMED Announces Definitive Agreement to Acquire SurgiQuest, Inc. Utica, New York, November 16, 2015 CONMED Corporation (NASDAQ: CNMD) today announced a definitive agreement to
Read more →CNMD: CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Third Quarter 2015 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke A. Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Third Quarter 2015 Utica, New York, October 21, 2015 --- CONMED Corporation (Nasdaq: CNMD) today announced financial result
Read more →CNMD: CONMED Corporation Luke Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2015 Financial Results Utica, New York
NEWS RELEASE CONTACT : CONMED Corporation Luke Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com CONMED Corporation Announces Second Quarter 2015 Financial Results Utica, New York, July 21, 2015 --- CONMED Corporation (Nasdaq: CNMD) today announced fi
Read more →CNMDCONMED Corporation Adds Two Health Care Executives to its Board of Directors Utica, New York
CONMED Corporation Adds Two Health Care Executives to its Board of Directors Utica, New York, July 1, 2015 CONMED Corporation (NASDAQ: CNMD) today announced that it has added David Bronson and John L. Workman to its Board of Directors, effective immediately. David and John are
Read more →CNMD: CONMED Corporation Luke Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com FOR RELEASE: 4:05 PM (Eastern)
NEWS RELEASE CONTACT : CONMED Corporation Luke Pomilio Chief Financial Officer 315-624-3202 LukePomilio@conmed.com RELEASE: 4:05 PM (Eastern) April 22, 2015 CONMED Corporation Announces First Quarter 2015 Financial Results Utica, New York, April 22, 2015 ----- CONMED
Read more →Competitive Position
How CNMD ranks across every disease it competes inCompetitive Position is a premium feature
See how CNMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial